(PharmaNewsWire.Com, July 14, 2017 ) Increasing incidence of diabetes and favourable government policies are driving the market growth. Usage of other alternative mode of medication like oral drugs is hindering the market growth. Whereas huge research and development investment by market players seem to be opportunity factor to the market.
Insulin pens in product segment hold the largest market share in 2015, owing to high popularity and easy to use property. In end user segment Patients/Homecare segment accounted for the largest market share. It is due to increase in health care expenditure. North America accounted for the highest market share as compared to other regions. The Asia Pacific region is expected to grow at a higher CAGR and is anticipated to account for the highest market share during forecast period because of rising diabetic patients in this region.
Some of the key players in the market include Abbott Laboratories, Animas Corporation (Johnson and Johnson) , Becton, Dickinson and Company, Biocon Limited, ELI Lilly and Company, F. Hoffmann-La Roche, Ltd., Insulet Corporation, Medtronic PLC, Novo Nordisk A/S, Sanofi, Tandem Diabetes Care, Inc., Wockhardt Ltd. and Ypsomed Holding AG.
Applications Covered: -Type II diabetes -Type I diabetes
End Users Covered: -Hospitals & Clinics -Patients/Homecare
Regions Covered: -North America-US-Canada-Mexico -Europe-Germany-France-Italy-UK -Spain -Rest of Europe -Asia Pacific-Japan -China -India -Australia -New Zealand -Rest of Asia Pacific -Rest of the World-Middle East-Brazil-Argentina-South Africa-Egypt
1 Executive Summary 2 Preface 3 Market Trend Analysis 4 Porters Five Force Analysis 5 Global Insulin Delivery Devices Market, By Application 6 Global Insulin Delivery Devices Market, By Product 7 Global Insulin Delivery Devices Market, By End User 8 Global Insulin Delivery Devices Market, By Geography 9 Key Developments 10 Company Profiling 10.1 Abbott Laboratories 10.2 Animas Corporation (Johnson and Johnson) 10.3 Becton, Dickinson and Company 10.4 Biocon Limited 10.5 ELI Lilly and Company 10.6 F. Hoffmann-La Roche, Ltd. 10.7 Insulet Corporation 10.8 Medtronic PLC 10.9 Novo Nordisk A/S 10.10 Sanofi 10.11 Tandem Diabetes Care, Inc. 10.12 Wockhardt Ltd. 10.13 Ypsomed Holding AG
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
